Gathering and analyzing patient experience data in a real-world setting is a key challenge for many

By HEOR Staff Writer

January 18, 2023

Gathering and analyzing patient experience data in a real-world setting is a key challenge for many. To explore this further, ISPOR in Vienna held a second plenary panel featuring experts in the field. What did they discuss?

The panel discussed the importance of rigor in choosing, implementing, and analyzing patient experience data in non-randomized, uncontrolled study designs. Dr. Burgos spoke about the Darwin EU initiative and the importance of stakeholder engagement and capacity building to facilitate patient experience data collection. Professor Devlin discussed the implementation of patient-reported outcome data capture and the PROMs initiatives in the UK, Canada, and New Zealand. Dr. Perfetto spoke about the Core Impact initiative in the US, which standardizes patient experience data collection and the use of core outcome sets.

The panel highlighted the need for further guidance and collaboration with stakeholders to ensure patient experience data is used to inform regulatory decision-making.

Reference url

Recent Posts

Biopharma Ecosystem Competitiveness: Post-COVID Challenges and Opportunities

By João L. Carapinha

February 20, 2026

Biopharma Ecosystem Competitiveness in Global Race A new EFPIA analysis compares bioph...
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
EMA Validates ENHERTU Breast Cancer Treatment Variation The European Medicines Agency (EMA) has validated a Type II Variation marketing authorization application for ENHERTU breast cancer treatment, specifically ENHERTU (trast...
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection with SGLT2 Inhibitors

By João L. Carapinha

February 19, 2026

Type 2 Diabetes Guidelines Reshape Initial Treatment The latest Type 2 Diabetes Guidelines from NICE (National Institute for Health and Care Excellence), published on 18 February 2026 as an update to guideline NG28 ("Type 2 diabe...